Quantcast

Latest JDRF Stories

2014-09-16 08:31:56

--New Collaboration will Increase Data Available to Artificial Pancreas Researchers -- NEW YORK and SAN FRANCISCO, Sept. 16, 2014 /PRNewswire-USNewswire/ -- JDRF, the leading research and advocacy organization funding type 1 diabetes (T1D) research, and Tidepool (TM), a Silicon Valley-based non-profit organization committed to reducing the burden of T1D, announced a partnership supported by JDRF funding for data access technology for people with T1D who use insulin pumps and...

2014-09-10 16:26:29

SAN DIEGO, Sept. 10, 2014 /PRNewswire/ -- ViaCyte, Inc., a privately held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of diabetes, called VC-01, announced today that it has been selected to receive a $16.6 million Accelerated Development Pathway Award from the California Institute for Regenerative Medicine (CIRM). According to CIRM, the Accelerated Development Awards were created to "provide selected applicants who are...

2014-09-10 08:29:58

ROSH HA-AYIN, Israel, September 10, 2014 /PRNewswire/ -- Beta-O2 announced today that it has received a $500K grant from JDRF. The grant will be used to help fund a $1M pilot human study of Beta-O2's ssAir bio-artificial pancreas, in development as a treatment and potential cure for type 1 diabetes (T1D). The two-year study, which will enroll eight participants at Uppsala University Hospital in Sweden, will evaluate the safety, survival and function of implanted human islets...

2014-08-26 23:10:27

The Western Pennsylvania Chapter of JDRF has named Susan Manzi, MD, Chair of the Department of Medicine at Allegheny Health Network, corporate chair of its 2014 Walk to Cure Diabetes event in Pittsburgh. Pittsburgh, PA (PRWEB) August 26, 2014 The Western Pennsylvania Chapter of JDRF has named Susan Manzi, MD, Chair of the Department of Medicine at Allegheny Health Network, corporate chair of its 2014 Walk to Cure Diabetes event in Pittsburgh. The JDRF Walk to Cure Diabetes in Pittsburgh...

2014-08-20 08:27:26

SOUTHAMPTON, England, August 20, 2014 /PRNewswire/ -- Phase I Trial of Plasma Kallikrein Inhibitor to be Conducted in the US KalVista Pharmaceuticals ("KalVista"), an ophthalmology company with a focus on diabetic macular edema (DME), today announces that it has begun a Phase I, First in Human, trial of its novel plasma kallikrein inhibitor, KVD001, for the treatment of DME. The study's Principal Investigator is Dr. Jennifer K Sun of the Beetham Eye Institute, Joslin...

2014-08-19 08:30:47

Company Plans to Immediately Initiate Phase 1/2 Clinical Trial SAN DIEGO, Aug. 19, 2014 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, announced today that the U.S. Food and Drug Administration ("FDA") has accepted the company's Investigational New Drug Application ("IND") for its VC-01(TM) candidate cell replacement therapy to treat type 1 diabetes. The company plans to promptly initiate a Phase 1/2 clinical trial which it believes to be the first...

2014-07-30 16:28:55

-- JDRF Calls for CGM Medicare Coverage to Help Improve Health Outcomes Among Seniors with T1D and Advance an Artificial Pancreas -- WASHINGTON, July 30, 2014 /PRNewswire-USNewswire/ -- Today U.S. Senators Susan Collins (R-ME) and Jeanne Shaheen (D-NH), Co-chairs of the Senate Diabetes Caucus, introduced legislation to ensure that seniors with type 1 diabetes (T1D) who are Medicare eligible have access to continuous glucose monitors (CGM) as prescribed by their physicians. The...

2014-07-25 23:04:27

New report from the Juvenile Diabetes Cure Alliance analyzes the JDRF’s revenue and spending during fiscal year 2013 to find research spending down by $50 million since 2008 peak, while all other expense categories increased. New York, New York (PRWEB) July 25, 2014 A report released by the Juvenile Diabetes Cure Alliance reviews JDRF’s revenue and spending during fiscal year 2013 (July 1, 2012- June 30, 2013). Outside of the US government’s National Institutes of Health (NIH), the...

2014-07-21 12:24:39

Passionate volunteer will now lead organization toward life-changing treatments on path to ultimate cure for type one diabetes (T1D) NEW YORK, July 21, 2014 /PRNewswire/ -- JDRF's International Board of Directors (IBOD) announced today the appointment of Derek Rapp, currently Vice Chair of the JDRF International Board of Directors, as its new President and CEO. http://photos.prnewswire.com/prnvar/20140721/128866 Rapp replaces Jeffrey Brewer who recently left his role as JDRF...

2014-07-17 16:25:37

NEW YORK, July 17, 2014 /PRNewswire/ -- JDRF, the leading research and advocacy organization funding type 1 diabetes (T1D) research announced today ViaCyte, Inc., a leading regenerative medicine company, has filed an Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA) seeking to initiate a Phase 1/2 clinical trial in patients with type 1 diabetes. The trial would evaluate the safety and efficacy of the VC-01(TM) product candidate, a stem...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'